ArticleProceedings of the American Thoracic Society2008
Mining the epigenome for methylated genes in lung cancer.
Article in Proceedings of the American Thoracic Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- MiR-338-3p improved lung adenocarcinoma byArchives of medical science : AMS · 2021Article
- Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma.Annals of translational medicine · 2020Article
- A novel CpG-based signature for survival prediction of lung adenocarcinoma patients.Experimental and therapeutic medicine · 2020Article
- Multiple biological functions of transcription factor 21 in the development of various cancers.OncoTargets and therapy · 2018Review
- Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PLoS genetics · 2017Article
- Article
- Sumoylation of TCF21 downregulates the transcriptional activity of estrogen receptor-alpha.Oncotarget · 2016Article
- Article
- Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- Protein expression and promoter methylation of the candidate biomarker TCF21 in gastric cancer.Journal of cancer research and clinical oncology · 2015Article
- Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Review
- Epigenetic regulation of cholesterol homeostasis.Frontiers in genetics · 2014Review
- Nesprins: from the nuclear envelope and beyond.Expert reviews in molecular medicine · 2013Review
- Review
- Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer.Toxicologic pathology · 2012Article
- Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.Genome research · 2012Article
- Sputum-based molecular biomarkers for the early detection of lung cancer: limitations and promise.Cancers · 2011Article
- Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.BMC medical genomics · 2011Article
- Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy.Journal of cellular and molecular medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer has become a global public health burden, further substantiating the need for early diagnosis and more effective targeted therapies. The key to accomplishing both these goals is a better understanding of the genes and pathways disrupted during the initiation and progression of this disease. Gene promoter hypermethylation is an epigenetic modification of DNA at promoter CpG islands that together with changes in histone structure culminates in loss of transcription. The fact that gene promoter hypermethylation is a major mechanism for silencing genes in lung cancer has stimulated the development of screening approaches to identify additional genes and pathways that are disrupted within the epigenome. Some of these approaches include restriction landmark scanning, methylation CpG island amplification coupled with representational difference analysis, and transcriptome-wide screening. Genes identified by these approaches, their function, and prevalence in lung cancer are described. Recently, we used global screening approaches to interrogate 43 genes in and around the candidate lung cancer susceptibility locus, 6q23-25. Five genes, TCF21, SYNE1, AKAP12, IL20RA, and ACAT2, were methylated at 14 to 81% prevalence, but methylation was not associated with age at diagnosis or stage of lung cancer. These candidate tumor suppressor genes likely play key roles in contributing to sporadic lung cancer. The realization that methylation is a dominant mechanism in lung cancer etiology and its reversibility by pharmacologic agents has led to the initiation of translational studies to develop biomarkers in sputum for early detection and the testing of demethylating and histone deacetylation inhibitors for treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.